Please Wait
Applying Filters...
menu
    • menu

    Digital Content for MolPort-001-840-190

    Client Email Product
    Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    MolPort-001-840-190

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 323Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Acasti Completes Enrollment In GTX-104 Phase 3 STRIVE-ON
    Acasti Completes Enrollment In GTX-104 Phase 3 STRIVE-ON

    25 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/25/2952856/0/en/Acasti-Announces-Completion-of-Patient-Enrollment-in-Pivotal-Phase-3-STRIVE-ON-Safety-Trial-of-GTX-104.html

    GLOBENEWSWIRE
    25 Sep 2024
    Share Share
    Acasti to Present at the Life Sciences Investor Forum
    Acasti to Present at the Life Sciences Investor Forum

    12 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/12/2945131/0/en/Acasti-to-Present-at-the-Life-Sciences-Investor-Forum.html

    GLOBENEWSWIRE
    12 Sep 2024
    Share Share
    Acasti To Participate In H.C. Wainwright Investment Conference
    Acasti To Participate In H.C. Wainwright Investment Conference

    05 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/05/2941525/0/en/Acasti-to-Participate-in-the-H-C-Wainwright-26th-Annual-Global-Investment-Conference.html

    GLOBENEWSWIRE
    05 Sep 2024
    Share Share
    Annora Pharma's Generic Nimodipine Receives Approvals in US
    Annora Pharma's Generic Nimodipine Receives Approvals in US

    09 Jul 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216937

    FDA
    09 Jul 2024
    Share Share
    Amneal Pharms LLC’s Generic Nimodipine Receives Tentative Approval In US
    Amneal Pharms LLC’s Generic Nimodipine Receives Tentative Approval In US

    14 May 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216256

    FDA
    14 May 2024
    Share Share
    Acasti Pharma Reports Fiscal Year 2023 Operational Results
    Acasti Pharma Reports Fiscal Year 2023 Operational Results

    23 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acasti-pharma-reports-fiscal-year-2023-operational-results-301860778.html

    PR NEWSWIRE
    23 Jun 2023
    Share Share